Cerevel Therapeutics Holdings Inc (CERE) Shares Plummet Below 1-Year High

The stock price of Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) has dropped by -0.02 compared to previous close of 42.35. Despite this, the company has seen a fall of -0.05% in its stock price over the last five trading days. Investopedia reported 2023-12-07 that Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

Is It Worth Investing in Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) Right Now?

Moreover, the 36-month beta value for CERE is 1.49. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for CERE is 87.00M and currently, short sellers hold a 8.00% of that float. On April 03, 2024, CERE’s average trading volume was 1.56M shares.

CERE’s Market Performance

The stock of Cerevel Therapeutics Holdings Inc (CERE) has seen a -0.05% decrease in the past week, with a 3.04% rise in the past month, and a 0.31% gain in the past quarter. The volatility ratio for the week is 0.69%, and the volatility levels for the past 30 days are at 0.79% for CERE. The simple moving average for the past 20 days is 0.71% for CERE’s stock, with a 32.37% simple moving average for the past 200 days.

Analysts’ Opinion of CERE

Many brokerage firms have already submitted their reports for CERE stocks, with TD Cowen repeating the rating for CERE by listing it as a “Market Perform.” The predicted price for CERE in the upcoming period, according to TD Cowen is $45 based on the research report published on December 08, 2023 of the previous year 2023.

JP Morgan, on the other hand, stated in their research note that they expect to see CERE reach a price target of $25. The rating they have provided for CERE stocks is “Neutral” according to the report published on November 20th, 2023.

Piper Sandler gave a rating of “Overweight” to CERE, setting the target price at $33 in the report published on September 28th of the previous year.

CERE Trading at 0.99% from the 50-Day Moving Average

After a stumble in the market that brought CERE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.87% of loss for the given period.

Volatility was left at 0.79%, however, over the last 30 days, the volatility rate increased by 0.69%, as shares surge +2.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.55% upper at present.

During the last 5 trading sessions, CERE fell by -0.05%, which changed the moving average for the period of 200-days by +19.67% in comparison to the 20-day moving average, which settled at $42.10. In addition, Cerevel Therapeutics Holdings Inc saw -0.14% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CERE starting from COLES N ANTHONY, who sale 50,000 shares at the price of $41.01 back on Mar 04 ’24. After this action, COLES N ANTHONY now owns 15,638 shares of Cerevel Therapeutics Holdings Inc, valued at $2,050,550 using the latest closing price.

COLES N ANTHONY, the Director of Cerevel Therapeutics Holdings Inc, sale 50,000 shares at $41.16 during a trade that took place back on Feb 29 ’24, which means that COLES N ANTHONY is holding 15,638 shares at $2,057,890 based on the most recent closing price.

Stock Fundamentals for CERE

The total capital return value is set at -0.39. Equity return is now at value -72.44, with -38.29 for asset returns.

Based on Cerevel Therapeutics Holdings Inc (CERE), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.76. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is -31.12.

Currently, EBITDA for the company is -441.64 million with net debt to EBITDA at 1.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.92.

Conclusion

To wrap up, the performance of Cerevel Therapeutics Holdings Inc (CERE) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts